254 related articles for article (PubMed ID: 28481188)
21. Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
Rau KM; Ou-Yang F; Chao TC; Kuo YL; Cheng TF; Chao TY; Chen DR; Tzeng YD; Wang BW; Liu CY; Hu MH; Lu YC; Ou WJ; Kuo CH; Chuang CH; Kan JY; Chen FM; Hou MF
Breast Cancer Res Treat; 2018 Aug; 170(3):583-591. PubMed ID: 29623575
[TBL] [Abstract][Full Text] [Related]
22. Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.
Iorfida M; Mazza M
Future Oncol; 2015; 11(15 Suppl):23-6. PubMed ID: 26235261
[TBL] [Abstract][Full Text] [Related]
23. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Casanova C; Verlicchi A; Mazza V; Dazzi C
Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
[TBL] [Abstract][Full Text] [Related]
24. Experience with eribulin in pretreated patients with advanced liposarcoma: a case series.
Paioli A; Setola E; Palmerini E; Cesari M; Longhi A
Future Oncol; 2020 Jan; 16(1s):25-32. PubMed ID: 31858818
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
[TBL] [Abstract][Full Text] [Related]
26. A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient.
Miano ST; Francini E; Petrioli R; Francini G
Future Oncol; 2020 Jan; 16(1s):33-38. PubMed ID: 31975628
[TBL] [Abstract][Full Text] [Related]
27. Eribulin mesylate for the treatment of breast cancer.
Cigler T; Vahdat LT
Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
[TBL] [Abstract][Full Text] [Related]
28. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
[TBL] [Abstract][Full Text] [Related]
29. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract][Full Text] [Related]
31. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F
Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of a third-line treatment with eribulin plus trastuzumab in a young breast cancer patient.
Scavelli C; Gallù F
Future Oncol; 2014 Nov; 10(14):2127-32. PubMed ID: 25471027
[TBL] [Abstract][Full Text] [Related]
33. [Eribulin in the treatment for metastatic breast cancer].
Manzyuk LV; Kovalenko EI; Artamonova E
Vopr Onkol; 2015; 61(2):195-8. PubMed ID: 26087597
[TBL] [Abstract][Full Text] [Related]
34. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
Martorana F; Vigneri P; Manzella L; Tirrò E; Soto Parra HJ
Future Oncol; 2020 Jan; 16(1s):9-13. PubMed ID: 31916463
[TBL] [Abstract][Full Text] [Related]
35. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
[TBL] [Abstract][Full Text] [Related]
36. Eribulin mesylate (Halaven) for breast cancer.
Med Lett Drugs Ther; 2011 Apr; 53(1362):30-1. PubMed ID: 21502935
[TBL] [Abstract][Full Text] [Related]
37. Dedifferentiated liposarcoma: when eribulin can make the difference.
Sbrana A; Paolieri F; Bloise F; Manacorda S; Nuzzo A; Sammarco E; Galli L; Falcone A
Future Oncol; 2020 Jan; 16(1s):21-24. PubMed ID: 31872768
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
[TBL] [Abstract][Full Text] [Related]
39. Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting.
Mougalian SS; Copher R; Kish JK; McAllister L; Wang Z; Broscious M; Garofalo D; Radtchenko J; Feinberg BA
Cancer Med; 2018 Sep; 7(9):4371-4378. PubMed ID: 30066497
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.
Medici M; Fossile E
Oncology; 2018; 94 Suppl 1(Suppl 1):3-5. PubMed ID: 30036863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]